Kamada Ltd
NASDAQ:KMDA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.65
6.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Kamada Ltd
Net Income (Common)
Kamada Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$15.7m
|
CAGR 3-Years
65%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
||
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Income (Common)
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
||
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$115.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
||
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$7.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
||
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Income (Common)
-â‚Ş29.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Income (Common)
-$21.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Net Income (Common)?
Net Income (Common)
15.7m
USD
Based on the financial report for Sep 30, 2024, Kamada Ltd's Net Income (Common) amounts to 15.7m USD.
What is Kamada Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-15%
Over the last year, the Net Income (Common) growth was 155%. The average annual Net Income (Common) growth rates for Kamada Ltd have been 65% over the past three years , -15% over the past five years .